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The American Thoracic Society (ATS) Core Curriculum updates clinicians annually in adult and pediatric pulmonary disease, medical critical care, and sleep medicine on a 3-or 4-year recurring cycle of topics. The 2017 course was presented in May during the annual International Conference and is published in four parts. This year, Part I covers topics in adult sleep medicine. A Continuing Medical Education (CME) exercise covering the contents of the Core Curriculum can be accessed online at www.thoracic.org until August 2020.
Insomnia: Pharmacological Therapies

Sarah Patel and Molly Billings
Insomnia is the most common sleep disorder, affecting approximately 33% of the general population (1) and with approximately 12-20 million U.S. adults reporting the use of prescription sleep aids (2) . Insomnia is characterized by difficulty falling asleep, maintaining sleep, and/or waking too early, resulting in insufficient sleep duration and/or quality. Insomnia may exist as a singular condition or comorbid with medical (e.g., cancer, chronic pain) and psychiatric (e.g., depression, anxiety) disorders.
Insomnia alone has been associated with reduced quality of life and functional impairment as well as increased risk for new onset of both psychiatric and medical conditions (3) . As such, insomnia is associated with substantial burden in terms of healthcare use (4) and workplace costs, with an estimated 8 days of individual lost work performance annually (5) . Although cognitive behavioral therapy for insomnia (CBT-I) is the mainstay of chronic insomnia treatment, medications can play an important role in initial management.
Classes of Pharmaceutical Agents for Insomnia
There are several classes of pharmaceuticals approved for the treatment of insomnia, and choosing the appropriate medication can be challenging. Because randomized trials directly comparing the efficacy of different insomnia pharmacotherapies are rare, selection should be based on insomnia features, patient characteristics and comorbidities, side effect profiles, and cost (Table 1) .
In patients who have primarily sleep-onset insomnia, a short-acting medication is a reasonable choice with the goal of minimizing next-day hypersomnolence (6) . Examples of shortacting medications include nonbenzodiazepine g-aminobutyric acid type A (GABA A ) receptor agonists (zaleplon and zolpidem), benzodiazepine GABA A agonists (triazolam), and melatonin ATS CORE CURRICULUM Table 1 .
(Continued ) Definition of abbreviations: BDZ = benzodiazepines; CNS = central nervous system; CYP1A2 = cytochrome P450 polypeptide 1A2; CYP2D6 = cytochrome P450 polypeptide 2D6; CYP3A4 = cytochrome P450 3A polypeptide 4; GABA = g-aminobutyric acid; GI = gastrointestinal; IA = intermediate acting; SA = short acting; SE = sleep efficiency; SL = sleep latency; SO = sleep onset;
Class of Medication
receptor agonists (ramelteon and melatonin). Importantly, GABA agonists have been shown to decrease objective sleep onset latency by only 10 minutes and subjective sleep onset latency by only 15-20 minutes (7) . The use of these medications, particularly the benzodiazepines, should be avoided in the elderly (8) .
For patients with sleep maintenance insomnia, longer-acting medications are preferred. Examples of longer-acting medications include GABA A receptor agonists (zolpidem tartrate, eszopiclone, estazolam), GABA A agonists (temazepam, lorazepam), H 1 antagonists (doxepin), orexin receptor antagonists (suvorexant), and sedating antidepressants (trazodone). For maintaining sleep, zaleplon or the sublingual form of zolpidem can be used, as long as the patient can remain in bed for at least 4 hours after taking the medication.
Nonbenzodiazepine GABA A receptor agonists have moderate efficacy in improving sleep outcomes and have been shown to reduce sleep onset latency and increase total sleep time (TST) perception. However, they can also lead to significant parasomnias, such as sleep eating and sleep driving (6) . In 2013, the U.S. Food and Drug Administration (FDA) recommended using a smaller dose of zolpidem for women. The long-term use of hypnotics has also been associated with dementia, fractures due to falls, and impaired cognition (6) , and recent studies have shown an increased association with malignancy in those taking higher doses (9) .
Benzodiazepines reduce sleep onset, prolong stage 2 sleep, and may reduce REM sleep (7) . Their key adverse side effects include residual daytime sedation, drowsiness, dizziness, lightheadedness, cognitive impairment, motor incoordination, falls, fractures, and dependence, with older adults being more susceptible (8) . Overall, benzodiazepines are not recommended for treatment of chronic insomnia.
Melatonin agonists have been shown to improve some sleep parameters; however, the effect is small. A meta-analysis of 11 trials showed that ramelteon (which binds to melatonin receptors with a higher affinity than melatonin) improved sleep onset by 3.6 minutes (10). Although adverse effects of melatonin agonists are typically milder, they can cause residual daytime somnolence.
Suvorexant, an inhibitor of orexin (a wakefulness neurotransmitter) receptors in the hypothalamus, was approved by the FDA in 2014 for insomnia (11) . In a large multicenter trial, it was shown to improve TST by 23 minutes, and it is costly.
Antidepressants with sedating effects have long been used offlabel in the treatment of insomnia. Doxepin and trazodone both have central anticholinergic and antihistamine effects (12) , and trazodone additionally can cause ventricular arrhythmias in the elderly. Trazodone leads to improved subjective sleep latency, sleep duration, and wake after sleep onset compared with placebo (13) . It should be reserved for use in patients with insomnia and concomitant depression because there is limited data on its use in patients with insomnia without depression (12, 13) . Other sedating, centrally acting medications commonly used for insomnia include mirtazapine, olanzapine, amitriptyline, and gabapentin. Their use is off-label but can be considered if insomnia is comorbid with the appropriate drug indication (e.g., depression or neuropathic pain).
Diphenhydramine is one of the most commonly used over-the-counter sleep aids; however, there is little evidence that it improves insomnia, and it may cause diminished cognitive function, as well as next-day hypersomnolence, delirium, and dry mouth. Therefore, it should not be used for insomnia, and side effects should be discussed with the elderly (6).
Treatment Considerations
The long-term use of sedative-hypnotics has been associated with an increased risk of morbidity and potentially mortality. Patients with reported hypnotic use had approximately 4.6 times the hazard of dying compared with nonusers, with an associated dose-response effect seen (9) . The Beers criteria were developed in 1991 to ensure safe medication use in individuals over 65 years of age. In 2015, the American Geriatrics Society updated the Beers criteria to include renal dose adjustment and drug-drug interactions, and it added nonbenzodiazepine GABA A receptor agonists to the list of drugs to be avoided in the treatment of insomnia because these were found to have similar adverse events in the elderly to those of benzodiazepines (14) .
In 2016, the FDA released a safety alert regarding the combined use of opioid medicines with benzodiazepines or other drugs that depress the central nervous system because the combination can result in serious adverse reactions, including respiratory depression and death. Thus, polypharmacy needs to be avoided in those with comorbid conditions.
Pharmacological treatment for insomnia should thus always be accompanied by patient education regarding treatment goals, expectations, safety concerns, potential side effects, and drug interactions. Pharmacological treatment ideally should be used only for short-term management of insomnia in conjunction with CBT-I or when addressing other underlying conditions contributing to insomnia.
Insomnia: Nonpharmacological Therapies
Elaine Boland and Philip Gehrman Individuals seeking treatment for insomnia are most frequently offered pharmacological management for their symptoms. However, sleep medications have significant side effects, as detailed above, as well as the risk for tolerance and dependence (1) .
CBT-I is a well-studied nonpharmacological intervention for insomnia (2) . CBT-I is based on the behavioral model of insomnia, also referred to as the "3 P model." This model identifies the predisposing, precipitating, and perpetuating factors involved in the development and maintenance of insomnia (3) . Predisposing factors are those that may make an individual more susceptible to developing insomnia, such as genetic predisposition or particular personality traits. Precipitating factors may be more proximally related to the onset of insomnia. For instance, experiencing a stressful event (e.g., divorce, job loss) or having an illness or injury can be related to the types of sleep difficulties that lead to development of insomnia. Perpetuating factors maintain insomnia, often despite remission of the precipitating event. These types of factors include new sleep habits (e.g., worrying in bed, going to bed at erratic hours, napping) as well as dysfunctional or irrational beliefs about sleep that developed during the course of the stressful event.
CBT-I was designed to help patients modify their sleep-related thoughts and behaviors to establish new, healthy sleep habits. The behavioral strategies implemented in CBT-I are designed to help patients (1) regularize their sleep routines, (2) reduce presleep cognitive and physiological hyperarousal, (3) modify conditioned arousal associated with the bed and sleep environment using stimulus control therapy, and (4) reduce daytime napping. Generating a regular sleep routine helps patients strengthen their homeostatic sleep drive while also providing behavioral "time cues" to help maintain a regular biological rhythm. Reducing daytime napping also helps preserve and strengthen the sleep drive. Relaxation strategies such as deep breathing, guided imagery, and progressive muscle relaxation are taught in conjunction with the strategy of generating a "buffer zone" to help individuals wind down and prepare for sleep. Patients are also taught to get out of bed when not sleeping and to use the bed only for sleeping to help extinguish conditioned arousal to the bed. Another behavioral strategy, termed "sleep restriction therapy," limits the time allowed in bed to the time actually spent sleeping, the rationale being that slight sleep deprivation will consolidate the sleep period, reduce onset latency, and help effect deeper sleep (4). Sleep restriction is not indicated for all individuals, however, and is generally contraindicated in individuals with excessive daytime sleepiness, significant parasomnias, or seizure disorder, as well as in those with bipolar disorder.
CBT-I also aims to reduce dysfunctional beliefs and attitudes about sleep. Techniques include identifying the "activators" (events that lead to thoughts), the thoughts themselves, the consequences (e.g., emotions or behaviors associated with the thoughts), and then disputing these negative thoughts regarding sleep. This is done by examining evidence for the dysfunctional thought, challenging the thought's validity, and coming up with a more rational way of thinking about sleep.
Implementation
CBT-I can easily be adapted and implemented in primary care and medical settings. If offering the full treatment is not possible, patients may derive benefit from the careful selection of one or two targeted strategies to help improve their symptoms. Asking some specific questions about the patient's sleep patterns (e.g., "Do you have a regular bedtime?" or "Do you often nap during the day?") can help identify which strategies might be most beneficial. Gauging a person's willingness to change his or her sleep patterns is also an important factor to consider because the treatment is not likely to be effective in unmotivated patients.
CBT-I can also be implemented via Internet and self-help interventions. Research has shown Internet delivery of CBT-I to be an effective and well-tolerated treatment for individuals with insomnia, especially those who may experience difficulties attending regular in-person appointments (5) . CBT-I offered in a self-help capacity has also been shown to have small to moderate treatment effects for individuals with insomnia, and thus it may represent another option for patients whose symptoms warrant intervention but who may be reluctant or unable to engage in CBT-I treatment with a practitioner (6) . Taking steps to identify the treatment needs and motivations of patients with insomnia will thus enable appropriate treatment matching to an array of available and effective modalities.
Comorbid Sleep and Psychiatric Disorders
Melisa Chang and Jennifer L. Martin
Sleep disorders commonly cooccur with psychiatric illness, and psychiatric comorbidities can impact the diagnosis and management of sleep disorders. Clinicians treating patients with sleep disorders should be particularly aware of the role of comorbid depression and anxiety disorders in diagnosis and treatment. Specifically, patients with insomnia commonly have comorbid depression and anxiety, as do patients with sleep-disordered breathing (SDB). Practitioners may thus find it difficult to identify which underlying disorder accounts for a given patient's symptoms. Recent research suggests that treatment of sleep disorders concurrently in patients with comorbid psychiatric disorders leads to better clinical outcomes than treating each disorder sequentially.
Fortunately, there is no evidence that concurrent treatment attenuates the beneficial effects of treatment for either sleep disorders or psychiatric symptoms. However, it is important to be aware that some pharmacological treatments for psychiatric disorders (e.g., antidepressant medications) have the potential to negatively impact sleep quality or exacerbate symptoms of sleep disorders. In these cases, the benefits of psychiatric medications must be weighed against the potential negative impact on sleep-related symptoms.
Depression in Patients with Sleep Disorders
Depressed mood is common among patients with sleep disorders and can impact the approach to diagnosis and treatment (Table 2) . Studies show that rates of depression in patients with obstructive sleep apnea (OSA) range from 7 to 63%, depending on the specific patient population (1). On one hand, evaluating symptoms of depression in patients with SDB is important because depression can negatively impact compliance with positive airway pressure (PAP) therapy (2) . On the other hand, if adequate PAP compliance is achieved, PAP can improve symptoms of depression, particularly among women and those with moderate to severe SDB (3).
Patients with insomnia also commonly experience symptoms of depression, and although historically insomnia symptoms were addressed only once depression was treated, recent studies have challenged this approach. CBT-I and the benefits of improvement in insomnia are no less effective in the context of comorbid depressive disorders, though those with comorbid depression are less likely to achieve full remission of their insomnia. CBT-I has also been shown to reduce symptoms of depression significantly (4) . A recent study combining CBT-I with pharmacotherapy for depression showed that improvements in insomnia mediated the antidepressant effect of medications (5) . A second study of predictors of antidepressant response to mirtazapine found that early improvements in insomnia symptoms were associated with a greater likelihood of remission of depression (6) . Taken together, these findings suggest that concurrent treatment of insomnia with CBT-I and antidepressant medications is likely to achieve optimal benefits for patients with comorbid depression and insomnia.
Anxiety in Patients with Sleep Disorders
Comorbid anxiety disorders such as generalized anxiety disorder, post-traumatic stress disorder (PTSD), and panic disorder can impact the diagnosis and treatment of patients with sleep disorders (Table 3 ). The prevalence of anxiety in patients with OSA has been reported to be between 11 and 70% (1). In one study in which researchers evaluated patients with suspected OSA, a higher prevalence of anxiety was noted in women, patients with excessive daytime sleepiness, single status, and lower education level (7) . It was also noted that anxiety and depression coexisted in 35% of patients. Some studies have shown that anxiety significantly declines after 6 months of continuous positive airway pressure (CPAP) treatment (8); however, anxiety can also be a barrier to PAP adherence, particularly if PAP use exacerbates anxiety by creating physical discomfort or 
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claustrophobia. When anxiety symptoms make PAP therapy difficult, behavioral approaches to reduce anxiety are beneficial. For example, a desensitization protocol can be used to help patients gradually get used to using PAP. In other instances, separate treatment for anxiety is required (e.g., in comorbid PTSD). Insomnia and anxiety disorders commonly cooccur. For example, more than 50% of women military veterans with insomnia also have PTSD, whereas rates of PTSD among those without insomnia are less than 25% (9) . Treatment of the insomnia component with CBT-I can improve symptoms of anxiety. The magnitude of benefits in insomnia symptoms normally achieved with CBT-I are similar in the context of comorbid anxiety disorders; however, as with depression, those with comorbid anxiety are less likely to achieve full remission of their insomnia (4). Concurrent treatment of anxiety disorders with evidence-based interventions may therefore be needed to optimally treat insomnia. 
OSA: Diagnosis
Sulaiman Khadadah and Marta Kaminska
Multiple questionnaires and prediction models using different combinations of physical examination or clinical history findings have been studied as diagnostic tools for OSA (1) . The advantage of these tools is that they use readily available information, are easily administered, and provide immediate results to help guide clinical decision making. Unfortunately, the overall level of evidence for these questionnaires is low, and none are sufficiently accurate to make a diagnosis of OSA without additional testing (Table 4 ). In conjunction with clinical evaluation, however, they can be used to estimate pretest probability and choose appropriate testing modalities (2). Recognized risk factors for OSA include witnessed apneas, daytime hypersomnolence, gasping or choking, loud snoring, obesity, and hypertension.
Testing for OSA
Sleep studies have traditionally been classified into four types ( 
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In adults, OSA is defined as the presence of five or more obstructive respiratory events per hour in the presence of symptoms or 15 or more obstructive respiratory events per hour in the absence of symptoms. Pediatric OSA is defined as the presence of symptoms with at least one obstructive event per hour or an obstructive hypoventilation pattern on PSG (7). Obstructive events include obstructive and mixed apneas, hypopneas, and respiratory effortrelated arousals (Table 6 ). Respiratory events detected by PSG can be expressed as an apnea-hypopnea index (AHI) or a respiratory disturbance index (RDI), the latter including respiratory effort-related arousals in addition to apneas and hypopneas ( Table 7 ). The AHI is the preferred index for defining and grading the severity of OSA when PSG is performed (7, 8) . Both RDI and AHI are linked to clinical outcomes, but most cardiovascular outcomes are linked with the AHI. With HSAT, the lack of EEG leads to inaccuracies when measuring arousals or TST. Rather, monitoring time is recorded, which is usually longer than TST. This results in a significant reduction in the number of events detected (no hypopneas with arousal) and also an increased time in the denominator for the index. When reporting HSAT results, the use of the respiratory event index is recommended to reflect these differences compared with AHI or RDI obtained from PSG. However, if TST is measured (e.g., using actigraphy), then AHI from HSAT can be reported (8) . The prevalence and severity of OSA thus varies depending on the type of test used.
Another factor that significantly affects sleep testing results is the scoring system used, particularly the definition of hypopnea (Table 6) . Using the currently recommended definition of hypopnea from the American Academy of Sleep Medicine (AASM), termed the "AASM 3%," the AHI is substantially increased compared with the previously recommended AASM 4% definition. Although initial data had shown that the minimum desaturation linked to clinically relevant outcomes was 4% (9), more recent data suggest that 3% desaturation is linked to increased cardiovascular risk, atrial fibrillation, and stroke (10) . Hence, the AASM 3% definition is currently preferred, though it remains somewhat controversial (10).
Conclusions
Marked variability remains in objective testing for OSA; therefore, it remains imperative that OSA testing be performed in conjunction with a comprehensive evaluation by a qualified sleep specialist (3).
OSA: PAP Therapies
Rahul Sharma and Lisa Wolfe
In 1981, Sullivan and colleagues described the first successful noninvasive treatment for OSA: CPAP delivered through the nares. Since that time, PAP devices have undergone major technological advances to improve comfort, efficacy, and cost. The principle of treatment, however, remains the same-PAP functions as a pneumatic splint in an effort to eliminate the recurrent pharyngeal airway occlusion that defines the pathophysiology of OSA. Patients with narrow upper airways due to altered anatomy (such as from enlarged uvula, tonsils, or a high-arched palate), reduced upper airway muscle activity at sleep onset, and obesity are more likely to experience obstructive apneas ( Table 8 ). The upper airway is theorized as a Starling resistor whereby the weak, nonrigid part of the pharynx collapses if transmural pressure exceeds intraluminal pressure. The pressure at which this occurs is known as the "pharyngeal critical opening pressure" (1) . Positive pressure applied upstream of the occluding pharyngeal segment, such as at the mouth or nose, increases intraluminal pressure above pharyngeal critical opening pressure at a time when muscle activity in the upper airway dilators is low and allows inspiratory flow to resume.
Benefits of Treatment
In randomized controlled trials (RCTs), nocturnal CPAP therapy for OSA has been shown to reduce daytime sleepiness, AHI, and sleep fragmentation while also improving quality-of-life measures, especially in patients with moderate to severe OSA (2, 3) . With regard to learning and cognition, CPAP does consolidate sleep and decrease awakenings, but the impact on neurocognitive measures was limited to executive function, with less impact on learning and memory, in a recent RCT (4). Moderate to severe OSA has been associated with a number of cardiovascular complications; data linking mild OSA with cardiovascular disease is also present but remains conflicting. CPAP has been shown to reduce blood pressure in patients with refractory hypertension, to improve left ventricular ejection fraction (LVEF) in those with systolic HF, and to reduce atrial fibrillation burden. However, in a recent RCT, the SAVE (Sleep Apnea Cardiovascular Endpoints) trial investigators did not find significant reduction in secondary cardiovascular events in those with moderate OSA (5). These findings may have limited applicability for all patient populations, though, because the study protocol excluded patients with severe daytime sleepiness and severe hypoxemia while accepting an overall low rate of adherence with CPAP therapy (3.3 h/night).
Evidence of CPAP benefit for patients with other comorbid conditions has been mixed. Multiple RCTs show a significant improvement in systolic blood pressure, albeit with a small effect Table 8 . Risk factors that increase development of apnea 
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size of 2.6 mm Hg (6); however, this effect increases to 7.2 mm Hg in patients with resistant hypertension (7). Whether CPAP therapy reduces the risk of ischemic stroke is debatable; however, use of CPAP in patients with OSA and acute ischemic stroke has been shown to significantly improve neurological recovery (8) . In patients with diabetes and concomitant OSA, the data on CPAP therapy shows mixed results, and the benefits remain uncertain. Recently, two RCTs have shown conflicting results regarding improving glycemic control with CPAP in patients with OSA (9); however, benefit was optimized if the sleep time on CPAP was maximized.
Alternatives to CPAP
Alternative modes of PAP therapy for OSA include auto positive airway pressure (APAP) and bilevel positive airway pressure (BIPAP). Certain devices allow an expiratory pressure reduction of 1-3 cm H 2 O with exhalation to increase comfort. Figure 1 depicts how these devices deliver pressure compared with CPAP. APAP devices alter pressure in response to changes in airflow and resistance. Manufacturers use proprietary algorithms, and currently there are no industry standards of operation. Generally, pressure is increased incrementally within the range of 4 and 20 cm H 2 O until airflow is normalized, at which point the pressure is reduced until another flow limitation is detected. APAP is useful in patients with uncomplicated OSA who have not had a CPAP titration study (10) .
BIPAP for OSA may be used to improve adherence for CPAPintolerant patients, who often report difficulty exhaling against a fixed pressure. BIPAP therapy is also a reasonable option for patients with coexisting hypoventilation syndromes (11) . Bilevel devices differ by manufacturer, based on proprietary features that assist in patient comfort or ensure adequate ventilation. Two examples, Bi-Flex (Philips Respironics, Murrysville, PA) and variable positive airway pressure (ResMed, San Diego, CA), are depicted in Figure 1 .
Long-Term Monitoring
With the advent of tracking systems, clinicians can download information directly from devices to monitor compliance, mask leak, and efficacy. An official statement from the ATS provides a clinical guideline on the use of adherence data (12) . Compliance is defined as CPAP use more than 4 hours per night for greater than 70% of nights. Mask leak metrics that require a change of interface vary among manufacturers. Efficacy is measured by residual AHI less than 10 events per hour.
Although assessment of adherence data is a key part of a clinician's role, it is only a small part of providing high-quality longterm care for patients with OSA. Table 9 lists 10 evidence-based steps for optimizing care for patients with OSA as recommended by the Adult OSA Quality Measures Workgroup (13) . ; Philips Respironics, Murrysville, PA), transient pressure decreases occur during exhalation to provide comfort. These are called "flex" (f). Auto positive airway pressure (APAP) devices have a stepwise increase in pressure until airflow is normalized (P tx ). After normalization, an incremental pressure decrease occurs until airflow limitation is again detected. Note that each pressure change occurs after minutes of monitoring. The Bi-Flex device (Philips Respironics) sets a fixed inspiratory positive airway pressure (IPAP) higher than the expiratory positive airway pressure (EPAP) and also has a flex decrease at the beginning of exhalation. The device rises to the IPAP after detection of a spontaneous breath, the trigger (t). The variable positive airway pressure (VPAP) device (ResMed) delivers IPAP with detection of a triggered breath; however, this device allows the setting of a minimum inspiratory time (T,min) and a maximum inspiratory time (T,max) for IPAP delivery. If the patient's spontaneous inspiratory flow ceases early, the machine will continue to provide IPAP until T,min is reached; in addition, the patient will not receive IPAP if attempting to inhale longer than T,max. 
Surgical Modalities
Historically, "uvulopalatopharyngoplasty" was a basket term describing a spectrum of surgical approaches to OSA, and this heterogeneity contributed to a body of evidence commonly interpreted as unfavorable. Uvulopalatopharyngoplasty itself as a sole procedure is no longer recommended, because it does not reliably normalize the AHI in most patients with OSA. Maxillomandibular advancement (MMA), which involves facial skeletal expansion followed by multilevel airway enlargement, alone or in a phased approach, is highly successful in patients with mandibular retrognathia and moderate to severe OSA, although this success is predicated on a low central apnea index. The literature supports an average AHI drop of 87% in carefully selected patients (1) . Combination or multilevel surgical procedures individualized to patient upper airway anatomy (Table 10) can be highly effective (2) . More generalized use of drug-induced sleep endoscopy, which simulates upper airway conditions during sleep, has enhanced precision for localizing airway obstruction and improved characterization of anatomic collapse. Drug-induced sleep endoscopy can therefore guide surgical procedure selection and meaningfully impact surgical outcomes (3). Tracheostomy, which surgically bypasses the upper airway, is now considered only after exhausting other nonsurgical and surgical options. In addition to curative intent surgery, aggressive treatment of nasal and sinus pathology with minimally invasive procedures with the aim of improving PAP tolerance and efficacy is becoming increasingly common. This often results in decreased PAP requirements (Table 11) .
Hypoglossal nerve stimulation (Inspire airway stimulator system; Inspire Medical Systems, Maple Grove, MN), a new surgical modality, is garnering increasing interest. A stimulator device equipped with both a sensing lead (placed intercostally) and a stimulating lead (placed around the hypoglossal nerve) is implanted beneath the chest wall. When timed to inspiration, hypoglossal nerve stimulation moves the tongue forward and widens the anteroposterior diameter of the airway. Studies conducted 
Weight Loss
Weight loss is considered adjunctive therapy for all obese patients with OSA. Even modest reductions in body weight as low as 10% have been shown to improve OSA severity and may predict an approximate change of 26 to 32% in AHI (5). Surgical weight loss in patients meeting bariatric surgery guidelines should also be considered because bariatric surgery was more effective than medical weight loss in dropping AHI in a recent meta-analysis (29/h vs. 11/h) (6).
Oral Appliances
Oral appliances (OAs) are an established OSA treatment alternative. They include mandibular advancement devices and tongue-retaining devices. Although less effective than PAP therapy, in a recent meta-analysis, OAs were shown to reduce AHI by a mean of 13.6 events/h, with the majority of included trials showing a greater than 50% reduction in AHI (7). Compared with CPAP, OAs equally improve daytime sleepiness and lead to meaningful improvements in blood pressure, cognitive function, and quality of life. When effective, OAs have a better compliance rate than CPAP. However, discontinuation due to tooth and jaw realignment and temporomandibular joint pain is common, and devices can be costly (8) . OAs are most effective in nonobese patients with mild to moderate, supine-predominant OSA. Other favorable predictors include mandibular retrognathia, younger age, female sex, and short soft palate.
Recent case series support combining OAs with PAP therapy, allowing for less PAP while decreasing temporomandibular joint discomfort (8) . There is a paucity of studies comparing OAs with surgical therapies for OSA. Both modalities appear effective in reducing AHI, but MMA appears to be more successful in achieving AHIs of fewer than five events per hour. Alternatively, a positive response to OAs preoperatively may indicate a favorable outcome after MMA (8) .
Other Non-PAP Modalities
High-flow oxygen in combination with hypnotics such as eszopiclone target the arousal threshold and high loop gain in some patients with OSA, and small studies have demonstrated significant improvements in AHI (9) . However, nocturnal oxygen is not recommended in isolation as therapy for OSA. In contrast to PAP, nocturnal oxygen alone was not associated with improved blood pressure outcomes in a recent large clinical trial, despite greater adherence to the latter compared with CPAP (10) .
In a small multicenter trial (11), nasal end-expiratory PAP (e.g., Provent nasal valve; Provent Sleep Therapy, Manchester, NH) demonstrated high compliance (88%) and decreased AHI by 50%, on average, suggesting effectiveness in selected patients; however, subsequent studies on this modality are lacking. Positional therapy in nonobese patients with mild to moderate supine-predominant OSA has been found to be noninferior to PAP in small trials (12) . Finally, personalized OSA management through careful upper airway phenotyping is garnering increased interest. Customized approaches combining multiple modalities will likely represent the future in OSA therapy (13). Central sleep apnea (CSA) is characterized by recurrent cessation or reduction in airflow accompanied by an absence of ventilatory effort during sleep. Clinicians generally treat symptomatic CSA to improve quality of life, nocturnal hypoxemia, and nocturnal sympathetic excitation. CSA is particularly common in patients with HF, and although treatment improves cardiac function, it may have a deleterious effect on survival in certain patients. This section provides a brief overview and update on the treatment of various forms of CSA.
Treatment of Primary CSA
Data are sparse for therapeutic options in CSA without an identifiable cause. CPAP, BIPAP with a backup rate, and adaptive servoventilation (ASV) are currently all recommended by the AASM as reasonable therapeutic options for primary CSA (1) . Limited data show that acetazolamide, a diuretic that induces metabolic acidosis, thereby reducing central chemoreflex sensitivity and decreasing the likelihood of developing CSA, may reduce AHI and improve symptoms. Sedative-hypnotics have been evaluated in a limited fashion for primary CSA; both zolpidem and triazolam are associated with a reduction in CSA severity (1), but they cannot be recommended, owing to a paucity of data and their side effect profile, especially in the elderly. Transvenous phrenic nerve stimulation has also been shown in a recent multicenter trial to improve both severity and symptoms in primary CSA (2); however, long-term results on mortality and other outcomes have yet to be reported.
Treatment of CSA in Congestive HF
Cheyne-Stokes respiration is a common pattern of CSA seen in patients with HF and is characterized by central apneas alternating with a hyperventilation phase exhibiting a crescendo-decrescendo flow pattern with a periodicity of 45-90 seconds. Medical optimization of HF is the mainstay of therapy: diuretics, afterload reduction, b-blockers, cardiac resynchronization therapy, left ventricular assist devices, and cardiac transplant have all been shown to improve Cheyne-Stokes respiration.
Various modalities of noninvasive ventilation have been studied for treatment of CSA in HF. CPAP can improve LVEF and may lower mortality among patients whose AHI is reduced to less than 15 per hour (3). CPAP is thus recommended by the AASM as initial therapy for CSA in HF, but among patients with persistently elevated AHI despite therapy adherence, alternative treatments should be considered. BIPAP with a backup rate is considered as an option only after CPAP or other modalities have been attempted (1) .
ASV is a mode of noninvasive ventilation that delivers variable inspiratory and expiratory pressure with a goal of stabilizing breathing patterns. Earlier studies suggested promise by demonstrating more effective resolution of CSA with ASV than with CPAP (4). This prompted a large multicenter randomized trial of ASV in HF with CSA, the SERVE-HF (Adaptive ServoVentilation for Central Sleep Apnea in Systolic Heart Failure) study (5) , which demonstrated a significantly increased risk of all-cause and cardiovascular mortality with ASV. On the basis of these results ASV is now contraindicated for treatment of CSA in patients with symptomatic HF, LVEF less than or equal to 45%, and AHI greater than 15 with greater than 50% central events. Among patients meeting these criteria previously initiated on ASV, patient-centered discussion about transitioning to alternative therapies is appropriate but should be done with caution because abrupt withdrawal of ASV may also carry a risk of worsening of HF symptoms.
Nocturnal oxygen therapy may stabilize ventilation due to either reduced CO 2 chemoreflex sensitivity or increased cerebral PCO 2 levels (6), and it has been shown to reduce CSA severity among patients with CSA due to HF, although less robustly than CPAP and without the benefit of LVEF improvement (7) . Guidelines recommend nocturnal oxygen for CSA related to HF in patients intolerant of noninvasive ventilation or as adjunctive therapy in patients whose CSA is persistent despite PAP therapy (1) . Acetazolamide can also improve both AHI and symptoms among patients with CSA due to HF, but it is currently recommended only after medical optimization of HF or if PAP therapy is not tolerated (1) . Last, transvenous phrenic nerve stimulation has been studied as a treatment in patients with CSA and HF; a recent multicenter trial demonstrated significant improvement in CSA severity and symptoms (8) .
Treatment of CSA Emergent during PAP Therapy CSA may occur in up to 20% of patients during initiation of PAP for OSA and is termed "complex sleep apnea syndrome." The majority of these patients experience spontaneous resolution of these central events over time with CPAP (9) . In a large retrospective study of 1,286 patients with a diagnosis of OSA, CPAP-emergent CSA was generally transitory and was eliminated within 8 weeks after CPAP therapy (10) . The prevalence of CPAP-persistent CSA was very low (1.5%), and severity of OSA, a central apnea index less than or equal to 5/h, and use of opioids were found to be potential risk factors. For patients with persistent central apneas and/or poor response to CPAP, ASV can be considered to improve treatment-emergent CSA on the basis of evidence derived from one study (11) .
Treatment of CSA Induced by Opiates
Chronic opioid use is commonly associated with the development of CSA. The pathogenesis involves effects on the central pattern generator, decreased respiratory drive, and increased chemosensitivity. There is evidence that cessation or modification of dosing of opioid therapy can lead to resolution of CSA, and it should be implemented as a first-line therapy. Although one small study demonstrated that ASV led to better symptom resolution than a backup rate (12) , no clinical RCTs have been performed using ASV in this setting. Clinical trials are ongoing regarding the role of ampakines, synthetic compounds that enhance glutamatergic neurotransmission and may counter opioid-induced respiratory depression by stimulating respiratory drive.
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